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Background. Erythropoietin has recently been found to have
cytoprotective effects in the central nervous system (CNS) and
retina. The purpose of this study was to determine if darbepoetin
alfa (DA) has cytoprotective properties in renal tissues.
Methods. DA was studied in LLC/PK1 and mesangial cells.
Renal cellular injury was induced in different experiments
by prostaglandin D2 synthase (PGDS), camptothecin, hydro-
gen peroxide, and hypoxia. Cellular proliferation and apop-
tosis were measured [apoptosis by terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate (dUTP) nick
end-labeling (TUNEL) assay or by caspase-3 activity]. In a sep-
arate experiment, an inactive form of erythropoietin alfa was
used to study receptor effects.
Results. DA protected against the antiproliferative effects
of PGDS. In both LLC/PK1 (TUNEL and caspase-3) and
mesangial cells (TUNEL), DA reduced the apoptotic stimu-
lus of PGDS. Epoetin alfa was also found to reduce apoptosis.
In LLC/PK1 cells, DA reduced apoptosis induced by camp-
tothecin, but not hydrogen peroxide. DA reduced LLC/PK1
apoptosis induced by hypoxia when added 24 hours before hy-
poxia, but not when given concurrent with the hypoxic stimulus.
Erythropoietin inactive did not protect against PGDS-induced
apoptosis.
Conclusion. DA has renal antiapoptotic effects for both toxic
and hypoxic stimuli. The effect may be mediated via the Ery-
thropoietin receptor.
Erythropoietin is a glycoprotein hormone produced in
adults primarily in the kidneys. It was originally under-
stood to be an erythropoietic stimulator, promoting sur-
vival of committed erythroid progenitor cells [1, 2]. The
hormone’s effects are signaled through the erythropoi-
etin receptor and increasingly understood transduction
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intermediates [3]. The recombinant forms of the hormone
have been used to effectively treat anemia in large num-
bers of patients with renal insufficiency, cancer, and other
disorders. Darbepoetin alfa (DA), an erythropoetic agent
with extended duration of action, has a serum half-life ap-
proximately three times as long as epoetin alfa [4].
Recently, it has been suggested that erythropoietin may
have effects outside of the hematopoietic system. Stimu-
lation of the erythropoietin receptor reportedly leads to
biologic actions in vascular endothelial and smooth mus-
cle cells [5, 6], and the uterus [7]. Moreover, recent studies
suggest that erythropoietin may have important cytopro-
tective effects in neurons in the brain and retina [8–11].
Hypoxia leads to increased erythropoietin production by
neurons via sensing by hypoxia inducible factor-1 [12].
It is reported that erythropoietin, via signal transduction
intermediates, greatly reduces neuronal apoptosis [13].
Generation of erythropoietin would seem to be a nor-
mal protective mechanism used by endangered neurons.
Moreover, with ischemic and traumatic brain insults in
animal models, exogenously administered erythropoietin
may reduce functional deficits and greatly reduce areas
of necrosis [8, 10]. The protective effect purportedly oc-
curs with administration prior to or concurrent with the
insult, or up to 3 hours after the insult.
Renal cellular injury occurs in a wide variety of acute
and chronic clinical settings. One route of renal cell
death, apoptosis, or programmed cell death, has been
demonstrated in diseases such as glomerulonephritis,
acute and chronic renal failure, diabetic nephropathy, and
polycystic kidney disease [14, 15]. Promotion of cellular
survival by reducing programmed cell death has the po-
tential to benefit many renal disease states. Recently, it
has been found that functional erythropoietin receptors
are produced in renal tubular and mesangial cells [16]. In
addition, Rosenberger et al [17] recently reported find-
ing hypoxia inducible factor-1 activity in renal tubular
cells. These intriguing findings suggest the possibility that
erythropoietin could have cytoprotective effects in the
kidneys, as it does in the brain. The purpose of these
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studies was to evaluate the ability of DA to positively af-
fect the balance between renal cellular proliferation and
programmed cell death.
METHODS
Cell culture
The pig kidney epithelial cell line LLC-PK1, provided
by Dr. Julia Lever, University of Texas, Houston, was
maintained in Dulbecco’s modified Eagle’s medium
(DMEM/F12) supplemented with 10% fetal calf
serum (FCS), 7.5% sodium bicarbonate, 15 mol/L
N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid
(HEPES), 200 mmol/L L-glutamate, 50 U/mL peni-
cillin, and 50 lg/mL streptomycin (Life Technologies,
Gaithersburg, MD, USA) at 37◦C in 5% CO2. The
mouse mesangial cell line was provided by Dr. Pravin
Singhal, North Shore-Long Island Jewish Hospital,
Manhasset, New York, and maintained in DMEM sup-
plemented with 10% heat-inactivated FCS, 3.7% sodium
bicarbonate, 1% HEPES, and 50 U/mL penicillin, and
50 lg/mL streptomycin. For terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate (dUTP)
nick end-labeling (TUNEL) assay, the cells were plated
at a density of 4.0 × 104 cells/cm2 onto Nunc Permanox
8-well chamber slides (Rochester, NY, USA), otherwise
cells were plated in 35 mm plates. In experiments in
which DA was used, cells were pretreated with DA for
1 hour prior to adding apoptotic stimulators for 16-hour
incubations. Hypoxic simulation was produced using a
controlled chamber with oxygen monitoring and carbon
dioxide/nitrogen gas.
Detection of apoptosis
Nuclear fragmentation consistent with apoptosis was
determined by the TUNEL assay as previously described
in Maesaka et al [14] using the ApopDetek Cell Death
Assay Kit (Enzo, Farmingdale, NY, USA). Confluent cells
were cultured as described above and then incubated
with prostaglandin D2 synthase (L-PGDS) (50 lg/mL)
and DA (50 ng/mL) individually and in combination for
16 hours. Cells were scored as TUNEL positive if they ap-
peared as condensed cells with dark nuclei. In all assays
the apoptotic index (AI) is calculated as the percentage
of TUNEL positive cells and represents at least 1000 cells
counted and is expressed as the mean ± SEM. In addi-
tion to the TUNEL assay described above, apoptosis was
confirmed by caspase-3 activity as previously described
[15].
Cell proliferation by [3H]-thymidine incorporation.
Cells were grown as described above until confluency.
Cells were then incubated with L-PGDS (50 lg/mL)
and DA (50 ng/mL) individually and in combination for
16 hours, followed by a pulse-label with [3H]-thymidine
(1 lCi/mL) for 3 hours. At the end of the incubation pe-
riod, the medium was removed and the cell monolayers
washed with ice-cold phosphate-buffered saline (PBS)
three times followed by one wash with ice-cold 10%
trichloroacetic acid (TCA) and incubated for 10 minutes
at 37◦C. The cells were solubilized by the addition of
200 lL of a 0.1% sodium dodecyl sulfate (SDS)/0.1 N
NaOH solution. After a 10-minute incubation, 100 lL of
cell lysate was added to 5 mL of scintillation fluid (In-
stagel, Packard, Wellesley, MA, USA) and the incorpo-
ration of [3H]-thymidine into DNA was determined by
liquid scintillation spectroscopy. Incorporation was ex-
pressed as dpm/mg of protein/hour.
Protein assay. Protein content of cell extracts were
determined with bicinchoninic acid [18].
Statistics
Results are expressed as mean ± SEM of at least three
independent experiments, each performed in duplicate
at different times. A paired Student t test was used to
compare the basal versus treated preparations and an
analysis of variance (ANOVA) was used to compare the
mean values between treatments. A value of P < 0.05 was
considered significant.
RESULTS
Effects of DA and L-PGDS challenge on LLC-PK1
proliferative activity
To assess the effects of L-PGDS and DA on prolifer-
ation, cells were incubated individually and in combina-
tion with each compound(s) for 16 hours. DA by itself had
no significant effect on [3H]-thymidine incorporation. In
contrast, L-PGDS incubation by itself led to a 33.1% re-
duction in proliferation (P < 0.05). When DA was added
to LLC-PK1 cells prior to L-PGDS incubation, cellular
proliferation was not significantly different than in con-
trol cells (Fig. 1).
Effects of DA, epoetin alfa, and L-PGDS challenge on
LLC-PK1 and mouse mesangial cell apoptotic activity
Incubation with DA by itself had no significant ef-
fect on basal LLC-PK1 apoptotic activity. Incubation for
16 hours with L-PGDS led to a 3.6-fold increase in apop-
tosis (P < 0.001). Pretreatment with DA significantly re-
duced the proapoptotic effect of L-PGDS (Fig. 2).
To determine whether the antiapoptotic effect was spe-
cific for darbepoetin alfa, or more generically an erythro-
poietin class effect, we repeated this experiment using
epoetin alfa at a concentration of 10 u/mL. Epoetin alfa
demonstrated essentially the same antiapoptotic effect,
reducing LLC-PK1 apoptosis after exposure to L-PGDS.
Mouse mesangial cells had a basal apoptotic in-
dex (TUNEL) of 5.3%. Incubation with DA did not
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Fig. 1. The effect of darbepoetin alfa (DA) on LLC-PK1 cell prolifer-
ation. Cells were either untreated (control), incubated separately with
DA (50 ng/mL) or prostaglandin D2 synthase (L-PGDS) (50 lg/mL)
for 16 hours, or pretreated with DA 1 hour prior to a 16-hour L-PGDS
exposure.
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Fig. 2. The effect of darbepoetin alfa (DA) on apoptosis induced by
prostaglandin D2 synthase (L-PGDS) in LLC-PK1 cells. Apoptosis
was measured by terminal deoxynucleotidyl transferase-mediated de-
oxyuridine triphosphate (dUTP) nick end-labeling (TUNEL) assay.
Cells were either untreated (control), incubated separately with DA
(50 ng/mL) or L-PGDS (50 lg/mL) for 16 hours, or pretreated with DA
1 hour prior to a 16-hour L-PGDS exposure. Results are reported as
fold-difference vs. controls (assigned value of 1).
significantly change the apoptotic index (P = NS). In-
cubation with L-PGDS caused the apoptotic index to
increase to 14.4%. Pretreatment with DA significantly
reduced the apoptotic effect of L-PGDS (Fig. 3).
Dose response of DA to protect against
L-PGDS–induced LLC-PK1 cell apoptosis measured
by TUNEL assay
In a separate incubation of LLC-PK1 cells with
L-PGDS, apoptotic activity was increased by 10.4-fold
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Fig. 3. The effect of darbepoetin alfa (DA) on apoptosis induced by
prostaglandin D2 synthase (L-PGDS) in mouse mesangial cells. Apop-
tosis was measured by terminal deoxynucleotidyl transferase-mediated
deoxyuridine triphosphate (dUTP) nick end-labeling (TUNEL) assay.
Cells were either untreated (control), incubated separately with DA
(50 ng/mL) or L-PGDS (50 lg/mL) for 16 hours, or pretreated with DA
1 hour prior to a 160-hour L-PGDS exposure.
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Fig. 4. The dose-effect of darbepoetin alfa (DA) on apoptosis induced
by prostaglandin D2 synthase (L-PGDS) in LLC-PK1 cells. Apopto-
sis was measured by terminal deoxynucleotidyl transferase-mediated
deoxyuridine triphosphate (dUTP) nick end-labeling (TUNEL) assay.
Cells were either untreated (control), incubated separately with DA
(varying concentrations from 0 to 100 ng/mL), or pretreated with DA
1 hour prior to a 16-hour L-PGDS (50 lg/mL) exposure.
compared to control cells (P < 0.05). When cells were
pretreated with DA at concentrations (doses) from 6.25
to 100 ng/mL, the apoptotic effect of L-PGDS was sig-
nificantly reduced. The protective effect increased pro-
gressively from doses of 6.25 ng/mL up to 25 ng/mL. At
a 25 ng/mL dose of darbepoetin alfa the protective effect
was essentially complete. The dose of 100 ng/mL had a
similar complete protective effect compared to the 25 to
50 ng/mL doses (Fig. 4).
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Fig. 5. The effect of darbepoetin alfa (DA) on apoptosis induced by
prostaglandin D2 synthase (L-PGDS) in LLC-PK1 cells. Apoptosis was
measured by caspase-3 assay. Cells were either untreated (control), in-
cubated separately with DA (50 ng/mL) or L-PGDS (50 lg/mL) for
16 hours, or pretreated with DA 1 hour prior to a 16-hour L-PGDS
exposure.
Effect of DA and L-PGDS challenge on LLC-PK1
apoptotic activity measured by caspase-3 assay
In the previous experiments, TUNEL assay was used
to measure apoptosis. To confirm these results, experi-
ments were performed with another apoptosis measure,
caspase-3 activity. Incubation of LLC-PK1 cells with DA
led to no significant change in caspase-3 activity. In con-
trast, incubation with L-PGDS by itself led to a significant
increase in caspase-3 activity (P < 0.05). When LLC-PK1
cells were pretreated with DA and then incubated with
L-PGDS, caspase-3 activity was not significantly different
than in control cells (Fig. 5).
Effects of DA on protection against apoptosis induced
by camptothecin and hydrogen peroxide
There was no significant difference between basal
apoptotic activity in control LLC-PK1 cells and those
treated with DA 10 ng/mL (P = NS). Incubation of cells
with camptothecin led to an increase in apoptotic activ-
ity compared to control cells from 2.4% to 16.1% (P <
0.001). When cells were pretreated with DA prior to incu-
bation with camptothecin, apoptotic index was reduced
to near baseline levels. Incubation of cells with hydro-
gen peroxide resulted in an increase in apoptotic index
from 2.4% to 15.9% (P < 0.001). Pretreatment with DA
had no protective effect on hydrogen peroxide induced
apoptosis (Fig. 6).
Effects of DA on protection against apoptosis induced
by hypoxia in LLC-PK1 cells
When grown in hypoxic conditions (3.5% oxygen) for
15 hours, apoptotic activity of LLC-PK1 cells measured
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Fig. 6. The effect of darbepoetin alfa (DA) on apoptosis induced by
camptothecin (5 lmol/L) and hydrogen peroxide (H2O2) (0.65 mmol/L)
in LLC-PK1 cells. Apoptosis was measured by terminal deoxynu-
cleotidyl transferase-mediated deoxyuridine triphosphate (dUTP) nick
end-labeling (TUNEL) assay. Cells were either untreated (control), in-
cubated separately with camptothecin or H2O2, or pretreated with DA
1 hour prior to a 16-hour exposure to camptothecin or H2O2.
by caspase-3 increased significantly. When cells were pre-
treated 24 hours before hypoxia with 10 ng/mL DA there
was a significant attenuation of apoptosis. In contrast,
when cells were treated with DA at the time of initiation
of hypoxia, there was no significant protection against
apoptosis (Fig. 7).
Study of inactive recombinant human erythropoietin
in LLC-PK1 cells
To evaluate the necessity of erythropoietin receptor
binding for protection against apoptosis, an experiment
was performed with inactive recombinant human ery-
thropoietin (kindly provided by Ken Aoki, Tony Loren-
zini, and Steven Elliott, Amgen, Inc., Thousand Oaks,
CA, USA). This substance is very similar to recombinant
human erythropoietin in physicochemical properties, but
does not activate the erythropoietin receptor. By itself, in-
active erythropoietin did not significantly alter the basal
apoptotic activity. Incubation of the cells with L-PGDS
led to a sharp increase in apoptotic activity. Treatment
with inactive recombinant human erythropoietin did not
significantly reduce the apoptotic activity induced by
L-PGDS (Fig. 8).
DISCUSSION
We studied the ability of DA to protect against apop-
tosis induced by renal toxins (L-PGDS, camptothecin,
and hydrogen peroxide) and hypoxia in porcine tubular
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Fig. 7. The effect of darbepoetin alfa (DA) on apoptosis induced by
hypoxia in LLC-PK1 cells. Apoptosis was measured by caspase-3 assay.
The first vertical bar represents basal apoptotic activity with cells grown
in ambient oxygen. The second vertical bar represents cells grown in
3.5% oxygen, with no DA added. The third vertical bar represents cells
grown in 3.5% oxygen, with DA (50 ng/mL) added 24 hours prior to
exposure to the hypoxic environment. The fourth vertical bar represents
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with initiation of exposure to the hypoxic environment.
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Fig. 8. The effect of inactivated erythropoietin inactive on apop-
tosis induced by prostaglandin D2 synthase (L-PGDS) in LLC-
PK1 cells. Apoptosis was measured by terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate (dUTP) nick end-
labeling (TUNEL) assay. Cells were either untreated (control), incu-
bated separately with erythropoietin inactive (50 ng/mL) or L-PGDS
(50 lg/mL) for 16 hours, or pretreated with erythropoietin inactive
1 hour prior to a 16-hour L-PGDS exposure.
cells, and a toxin (L-PGDS) in mouse mesangial cells. We
found that DA was highly protective against all challenges
except hydrogen peroxide. Moreover, the dose response
relationship was studied for protection against L-PGDS–
induced apoptosis. Indeed, there was a robust dose re-
sponse effect demonstrated. To determine whether the
cytoprotection was mediated via the erythropoietin re-
ceptor, we studied an altered form of erythropoietin that
does not interact with the receptor. We found that this
agent did not confer protection against apoptosis. Taken
together, these findings suggest that DA has important
protective effects in renal mesangial and tubular tissues,
probably mediated via the erythropoietin receptor. In ad-
dition, we studied epoetin alfa, and found that this agent
offered similar antiapoptotic effects in LLC-PK1 cells
compared to darbepoetin alfa. This suggests that the pro-
tective actions of darbepoetin alfa may represent a class
effect.
Erythropoietin is best understood as the body’s ma-
jor promoter of erythropoiesis [19]. It accomplishes this
by promoting survival of committed erythroid precursors,
primarily by inhibiting cellular apoptosis [20]. DA has five
amino acid differences from erythropoietin allowing for
two additional N-linked carbohydrates increasing the car-
bohydrate content from 40% to 51% [21, 22]. The struc-
tural change results in a longer serum half-life that allows
for an extended dosing interval [23]. We chose to study
this molecule, rather than recombinant human erythro-
poietin, because the extended serum half-life might be
advantageous for future anticipated clinical use in states
such as acute renal failure.
Recently, erythropoietin has been suggested to have
profound cytoprotective effects in neurons of the brain
and retina. For example, Brines et al [8] reported that
experimental ischemic or concussive brain injury in rats
could be reduced by 50% to 75% by treatment with ery-
thropoietin. The data suggest that erythropoietin gene ex-
pression in many tissues, including the brain, is regulated
by hypoxia via hypoxia-inducible factor-1 [24]. Indeed, in
the brain, hypoxia appears to induce production of both
erythropoietin and the erythropoietin receptor [9, 10, 25].
Subsequent local binding of erythropoietin to its receptor
may lead to activation of antiapoptotic signal pathways
[13] Indeed, Siren et al [10] reported that treatment with
erythropoietin led to nearly complete protection against
apoptosis after ischemic stroke in rats. The antiapoptotic
effect of erythropoietin are reported to greatly reduce
functional neurological deficits in animal studies [26–32].
The possibility that erythropoietin may play a cytopro-
tective role in the kidney is suggested by clinical evidence
associating erythropoietin treatment with improved
renal outcomes [33, 34]. Furthermore, Westenfelder,
Biddle, and Baranowski [16] report that erythropoietin
receptors are expressed in human, rat and mouse renal
cells, and that erythropoietin stimulated cell prolifera-
tion. More recently, Rosenberger et al [17] reports ex-
pression of hypoxia-inducible factor-1 in rat renal tubular
cells. While the kidney is critically linked with erythropoi-
etin production as part of regulated erythropoiesis, it is
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possible that erythropoietin could also have an important
effect in renal cytoprotection. In fact, other growth fac-
tors, such as epidermal growth factor, hepatocyte growth
factor and insulin-like growth factor-1 may have protec-
tive effects in experimental models of renal failure [35].
We tested the ability of DA to protect against toxins,
L-PGDS, camptothecin and hydrogen peroxide, and
against hypoxia. Of these, L-PGDS has special properties
of interest. This lipocalin-type prostaglandin, also known
as beta-trace protein, has effects on sleep, platelet func-
tion, vasomotor tone, and is an allergic and inflammatory
mediator [36]. Depending on its relative glycosylation,
its size ranges from 20 to 29 kD. With renal insufficiency,
L-PGDS accumulates in serum, and may act as a media-
tor of renal disease progression [14]. Moreover, we have
previously found L-PGDS to be a potent renal tubular
toxin [14].
We found that DA protected against L-PGDS induced
apoptosis in both renal tubular and mesangial cells. The
effect in tubular cells was dose dependent, with a peak
effect at a concentration that approximates serum levels
of DA achieved in anemia treatment. It appears that the
protective effect might be mediated via the erythropoi-
etin receptor, since inactive erythropoietin, which does
not interact with the receptor, did not provide protec-
tion. We found that DA reduced the antiproliferative ef-
fect of PGDS in LLC/PK1 cells, but did not itself have a
proproliferative effect. One possible explanation for this
finding is that DA (or erythropoietin generally) does not
function as a basal growth factor for renal tubular cells.
Rather, DA may promote cellular survival by preventing
apoptosis during toxic challenge.
DA also provided protection against apoptosis induced
by camptothecin. This alkaloid, an inhibitor of DNA
topoisomerase I, is a potent stimulus of apoptosis in a va-
riety of tissue types including renal carcinoma cells [37].
In contrast, we did not find DA to protect against apop-
tosis induced by hydrogen peroxide. The mechanistic im-
plications of this finding are a subject of further study.
Hypoxia is a potent stimulus for cellular apoptosis, and
we did find this to be true in LLC-PK1 cells. DA was not
protective when administered concurrently with the ini-
tiation of hypoxia, but was protective when incubated for
24 hours prior to hypoxia. This timing is in some contrast
to studies of neurologic injury in rats, where epoetin alfa
administration up to 6 hours after an ischemic insult has
been found to be protective [8].
DA’s antiapoptotic effects against toxins and hypoxia
suggest that the drug may eventually be found to be ben-
eficial for patients with acute renal failure. In normal
homeostasis, cellular survival depends on an interplay
between apoptotic and antiapoptotic stimuli that usually
balances strongly in favor of survival. In cellular injury,
such as in acute renal failure, the balance shifts, and apop-
tosis occurs [38–40]. Indeed, apoptosis plays an important
role on the pathogenesis of acute renal failure. However,
it is not yet entirely possible to separate out the relative
roles of apoptosis/necrosis in cell death in acute renal
failure. Our findings suggest that DA may help prevent
toxic and ischemic apoptosis and promote cellular sur-
vival. Moreover, DA might help in the process of postin-
jury recovery and regeneration. We would suggest that
animal studies and clinical trials of DA in acute renal
failure and other renal diseases may be warranted.
Reprint requests to Steven Fishbane, M.D., 200 Old Country Road,
Suite 135, Mineola, NY 11501.
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